LUGANO, Switzerland & OSAKA, Japan--(BUSINESS WIRE)--Healiva SA (Healiva) and C4U Corporation (C4U) are pleased to announce that they have entered into a strategic alliance agreement regarding the ...

BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food and ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...

Epidermolysis bullosa (EB) comprises a heterogeneous group of genetic disorders that result in extreme skin fragility, leading to blistering and tissue damage upon minimal mechanical stress. Beyond ...

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

Patients with the most severe form of a certain inherited disease have skin that is susceptible to wounds, some that never fully heal. For years, the only treatment was supportive care, including ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eluminex Biosciences has dosed the first patient in the ...

GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...

Abeona Therapeutics has received FDA approval for ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a ...

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The ...